Core Viewpoint - Keli Limited has submitted a listing application to the Hong Kong Stock Exchange, with China International Capital Corporation as the sole sponsor [1] Group 1: Company Overview - Keli Limited focuses on driving upgrades in the pharmaceutical supply chain through digital solutions, promoting innovation in the biomedicine and nutrition sectors [1] - The company's business includes pharmaceutical marketing, promotion, sales, and the research, production, and distribution of maternal and infant nutritional supplements [1] Group 2: Market Position - According to 2024 revenue estimates, Keli Limited ranks among the top ten in China's pharmaceutical marketing and promotion sales market, holding approximately 15.9% market share as the largest pediatric pharmaceutical marketing service provider [1] - The sales network of Keli Limited spans 31 provinces in mainland China, with over 1,500 distributors as of June 30, 2025, covering numerous clinics, pharmacies, and hospitals [1]